Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160


Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment.

Ferguson NM, Rodríguez-Barraquer I, Dorigatti I, Mier-Y-Teran-Romero L, Laydon DJ, Cummings DA.

Science. 2016 Sep 2;353(6303):1033-1036.


Assessment of benefits and risks associated with dengue vaccination at the individual and population levels: a dynamic modeling approach.

Coudeville L, Baurin N, Olivera-Botello G.

Expert Rev Vaccines. 2018 Aug;17(8):753-763. doi: 10.1080/14760584.2018.1503955. Epub 2018 Jul 31.


The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries.

Aguiar M, Stollenwerk N, Halstead SB.

PLoS Negl Trop Dis. 2016 Dec 21;10(12):e0005179. doi: 10.1371/journal.pntd.0005179. eCollection 2016 Dec.


Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge.

Halstead SB.

Am J Trop Med Hyg. 2016 Oct 5;95(4):741-745. doi: 10.4269/ajtmh.16-0222. Epub 2016 Jun 27.


Vaccines and immunization strategies for dengue prevention.

Liu Y, Liu J, Cheng G.

Emerg Microbes Infect. 2016 Jul 20;5(7):e77. doi: 10.1038/emi.2016.74. Review.


Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness.

Wichmann O, Vannice K, Asturias EJ, de Albuquerque Luna EJ, Longini I, Lopez AL, Smith PG, Tissera H, Yoon IK, Hombach J.

Vaccine. 2017 Oct 9;35(42):5535-5542. doi: 10.1016/j.vaccine.2017.08.066. Review.


The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study.

Flasche S, Jit M, Rodríguez-Barraquer I, Coudeville L, Recker M, Koelle K, Milne G, Hladish TJ, Perkins TA, Cummings DA, Dorigatti I, Laydon DJ, España G, Kelso J, Longini I, Lourenco J, Pearson CA, Reiner RC, Mier-Y-Terán-Romero L, Vannice K, Ferguson N.

PLoS Med. 2016 Nov 29;13(11):e1002181. doi: 10.1371/journal.pmed.1002181. eCollection 2016 Nov.


A recombinant live attenuated tetravalent vaccine for the prevention of dengue.

Guy B, Noriega F, Ochiai RL, L'azou M, Delore V, Skipetrova A, Verdier F, Coudeville L, Savarino S, Jackson N.

Expert Rev Vaccines. 2017 Jul;16(7):1-13. doi: 10.1080/14760584.2017.1335201. Epub 2017 Jun 7. Review. Erratum in: Expert Rev Vaccines. 2017 Jul;16(7):ix.


Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.

Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cortés M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M; CYD-TDV Dengue Vaccine Working Group.

N Engl J Med. 2015 Sep 24;373(13):1195-206. doi: 10.1056/NEJMoa1506223. Epub 2015 Jul 27.


Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate.

Gessner BD, Wilder-Smith A.

Vaccine. 2016 Apr 29;34(20):2397-401. doi: 10.1016/j.vaccine.2016.03.017. Epub 2016 Apr 5.


Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.

Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, Savarino S, Zambrano B, Moureau A, Khromava A, Moodie Z, Westling T, Mascareñas C, Frago C, Cortés M, Chansinghakul D, Noriega F, Bouckenooghe A, Chen J, Ng SP, Gilbert PB, Gurunathan S, DiazGranados CA.

N Engl J Med. 2018 Jul 26;379(4):327-340. doi: 10.1056/NEJMoa1800820. Epub 2018 Jun 13.


From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J.

Vaccine. 2011 Sep 23;29(42):7229-41. doi: 10.1016/j.vaccine.2011.06.094. Epub 2011 Jul 13. Review.


Cost-Effectiveness of Dengue Vaccination Programs in Brazil.

Shim E.

Am J Trop Med Hyg. 2017 May;96(5):1227-1234. doi: 10.4269/ajtmh.16-0810.


Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.

Briggs CM, Smith KM, Piper A, Huitt E, Spears CJ, Quiles M, Ribeiro M, Thomas ME, Brown DT, Hernandez R.

J Virol. 2014 Jun;88(12):6729-42. doi: 10.1128/JVI.00541-14. Epub 2014 Apr 2.


Development of Sanofi Pasteur tetravalent dengue vaccine.

Lang J.

Rev Inst Med Trop Sao Paulo. 2012 Oct;54 Suppl 18:S15-7. No abstract available.


Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.

Dayan GH, Galán-Herrera JF, Forrat R, Zambrano B, Bouckenooghe A, Harenberg A, Guy B, Lang J.

Hum Vaccin Immunother. 2014;10(10):2853-63. doi: 10.4161/21645515.2014.972131.


Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.

Simmons M, Burgess T, Lynch J, Putnak R.

Virology. 2010 Jan 20;396(2):280-8. doi: 10.1016/j.virol.2009.10.023. Epub 2009 Nov 13.


Call to action for dengue vaccine failure.

Mahalingam S, Herring BL, Halstead SB.

Emerg Infect Dis. 2013 Aug;19(8):1335-7. doi: 10.3201/eid1908.121864. No abstract available.


The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection.

Pitisuttithum P, Bouckenooghe A.

Expert Rev Vaccines. 2016 Jul;15(7):795-8. doi: 10.1080/14760584.2016.1189331. No abstract available.


Supplemental Content

Support Center